Recursion Pharmaceuticals looks like a falling knife despite a compelling idea behind the company. @WessexCapital calls it a financial disaster that is perpetually raising money. A large capital raise and the resulting drop would be the signal to consider it, perhaps around $1, as a lottery-style venture bet. x.com 

Ondas stock is being suppressed by constant dilution, an acquisition spree and a warrant overhang. It should not break out until the warrant overhang clears; a dip into the mid-$8s could make it worth revisiting. x.com 

Sidus Space's $58.5 million raise at $4.35 a share, about 27% below the $5.95 it traded at days earlier, is a classic dilutive raise into a momentum pump that destroys per-share value. It adds 13.45 million shares to a company with $3.4 million of 2025 revenue, down 28%, and a $29.5 million net loss, and the proceeds simply fund runway. The bearish signals after the pump point to FOMO buyers serving as exit liquidity. x.com  x.com